Evidence map›Paper›PMID 29486734›Full record

ArticleBMC cancer2018

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.

Heleen K Bronsveld, Marie L De Bruin, Jelle Wesseling, Joyce Sanders, Ingrid Hofland, Vibeke Jensen, Marloes T Bazelier, Bas Ter Braak, Anthonius de Boer, Peter Vestergaard and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Overcoming cancer therapeutic bottleneck by drug repurposing.Signal transduction and targeted therapy · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Heleen K BronsveldDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Marie L De BruinDivision of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, Netherlands.
Jelle WesselingDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Joyce SandersDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Ingrid HoflandCore Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Vibeke JensenDepartment of Pathology, Aarhus University Hospital THG, Aarhus, Denmark.
Marloes T BazelierDivision of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, Netherlands.
Bas Ter BraakDivision of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
Anthonius de BoerDivision of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, Netherlands.
Peter VestergaardDepartments of Clinical Medicine and Endocrinology, Aalborg University Hospital, Aalborg, Denmark.
Marjanka K SchmidtDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands. mk.schmidt@nki.nl.
The Netherlands Cancer Institute · NLOncode Institute · NLUtrecht University · NLAalborg University Hospital · DKAarhus University Hospital · DKLeiden University · NLUniversity of Copenhagen · DK

Funding

Seventh Framework Programme 282526
6 · The paper itself

Abstract

backgroundThe insulin receptor (INSR) and the insulin growth factor 1 receptor (IGF1R) play important roles in the etiology of both diabetes mellitus and breast cancer. We aimed to evaluate the expression of hormone and insulin-related proteins within or related to the PI3K and MAPK pathway in breast tumors of women with or without diabetes mellitus, treated with or without insulin (analogues).

methodsImmunohistochemistry was performed on tumor tissue of 312 women with invasive breast cancer, with or without pre-existing diabetes mellitus, diagnosed in 2000-2010, who were randomly selected from a Danish breast cancer cohort. Women with diabetes were 2:1 frequency matched by year of birth and age at breast cancer diagnosis to those without diabetes. Tumor Microarrays were successfully stained for p-ER, EGFR, p-ERK1/2, p-mTOR, and IGF1R, and scored by a breast pathologist. Associations of expression of these proteins with diabetes, insulin treatment (human insulin and insulin analogues) and other diabetes medication were evaluated by multivariable logistic regression adjusting for menopause and BMI; effect modification by menopausal status, BMI, and ER status was assessed using interactions terms.

resultsWe found no significant differences in expression of any of the proteins in breast tumors of women with (n = 211) and without diabetes (n = 101). Among women with diabetes, insulin use (n = 53) was significantly associated with higher tumor protein expression of IGF1R (OR = 2.36; 95%CI:1.02-5.52; p = 0.04) and p-mTOR (OR = 2.35; 95%CI:1.13-4.88; p = 0.02), especially among women treated with insulin analogues. Menopause seemed to modified the association between insulin and IGF1R expression (p = 0.07); the difference in IGF1R expression was only observed in tumors of premenopausal women (OR = 5.10; 95%CI:1.36-19.14; p = 0.02). We found no associations between other types of diabetes medication, such as metformin, and protein expression of the five proteins evaluated.

conclusionsIn our study, breast tumors of women with pre-existing diabetes did not show an altered expression of selected PI3K/MAPK pathway-related proteins. We observed an association between insulin treatment and increased p-mTOR and IGF1R expression of breast tumors, especially in premenopausal women. This observation, if confirmed, might be clinically relevant since the use of IGF1R and mTOR inhibitors are currently investigated in clinical trials.

Indexed as

Diabetes ComplicationsSignal TransductionBreast NeoplasmsCross-Sectional StudiesDiabetes MellitusErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryInsulinMAP Kinase Signaling SystemMiddle AgedMitogen-Activated Protein Kinase 1Phosphatidylinositol 3-KinasesReceptor, IGF Type 1EGFR protein, humanErbB ReceptorsIGF1R protein, humanInsulinMAPK1 protein, humanMitogen-Activated Protein Kinase 1MTOR protein, humanPhosphatidylinositol 3-KinasesReceptor, IGF Type 1Receptors, SomatomedinTOR Serine-Threonine KinasesBreast cancerDiabetes mellitusImmunohistochemistryInsulinInsulin growth factor 1 receptorMAPK pathwaymTORPI3K pathway

Identifiers

PMID29486734
PMCPMC6389252
OpenAlexW2789641335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.